Header Logo

Connection

KEVIN GAREY to Microbial Sensitivity Tests

Back to Details
This is a "connection" page, showing publications KEVIN GAREY has written about Microbial Sensitivity Tests.
KEVIN GAREY
Connection Strength
3.953
Microbial Sensitivity Tests
  1. Fidaxomicin resistance in Clostridioides difficile: a systematic review and predictive modeling with RNA polymerase binding sites. Antimicrob Agents Chemother. 2024 Dec 05; 68(12):e0120624.
    View in: PubMed
    Score: 0.763
  2. Accelerate PhenoTestTM BC Kit Versus Conventional Methods for Identification and Antimicrobial Susceptibility Testing of Gram-Positive Bloodstream Isolates: Potential Implications for Antimicrobial Stewardship. Ann Pharmacother. 2018 08; 52(8):754-762.
    View in: PubMed
    Score: 0.482
  3. Reduced Vancomycin Susceptibility in Clostridioides difficile Is Associated With Lower Rates of Initial Cure and Sustained Clinical Response. Clin Infect Dis. 2024 07 19; 79(1):15-21.
    View in: PubMed
    Score: 0.187
  4. Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of Clostridioides difficile. Antimicrob Agents Chemother. 2024 03 06; 68(3):e0162123.
    View in: PubMed
    Score: 0.181
  5. Systems biology evaluation of refractory Clostridioides difficile infection including multiple failures of fecal microbiota transplantation. Anaerobe. 2021 Aug; 70:102387.
    View in: PubMed
    Score: 0.150
  6. Clostridioides difficile ribotype 106: A systematic review of the antimicrobial susceptibility, genetics, and clinical outcomes of this common worldwide strain. Anaerobe. 2020 Apr; 62:102142.
    View in: PubMed
    Score: 0.136
  7. Rezafungin (CD101), a next-generation echinocandin: A systematic literature review and assessment of possible place in therapy. J Glob Antimicrob Resist. 2018 09; 14:58-64.
    View in: PubMed
    Score: 0.120
  8. Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates. Antimicrob Agents Chemother. 2015 Sep; 59(9):5405-12.
    View in: PubMed
    Score: 0.100
  9. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin Infect Dis. 2014 Sep 15; 59(6):819-25.
    View in: PubMed
    Score: 0.093
  10. Treatment of Candida famata bloodstream infections: case series and review of the literature. J Antimicrob Chemother. 2013 Feb; 68(2):438-43.
    View in: PubMed
    Score: 0.083
  11. Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches. Ann Pharmacother. 2012 Jul-Aug; 46(7-8):1086-96.
    View in: PubMed
    Score: 0.081
  12. Inhibition of biofilm formation by esomeprazole in Pseudomonas aeruginosa and Staphylococcus aureus. Antimicrob Agents Chemother. 2012 Aug; 56(8):4360-4.
    View in: PubMed
    Score: 0.081
  13. Clinical outcomes of patients infected with carbapenem-resistant Acinetobacter baumannii treated with single or combination antibiotic therapy. J Med Assoc Thai. 2011 Jul; 94(7):863-70.
    View in: PubMed
    Score: 0.076
  14. In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases. Southeast Asian J Trop Med Public Health. 2011 Jul; 42(4):890-900.
    View in: PubMed
    Score: 0.076
  15. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J Antimicrob Chemother. 2011 Sep; 66(9):2146-51.
    View in: PubMed
    Score: 0.076
  16. Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections. Expert Rev Anti Infect Ther. 2010 Jul; 8(7):747-60.
    View in: PubMed
    Score: 0.071
  17. Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther. 2010 May; 8(5):555-64.
    View in: PubMed
    Score: 0.070
  18. In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas. J Clin Pathol. 2010 Apr; 63(4):355-8.
    View in: PubMed
    Score: 0.069
  19. Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010 Mar; 54(3):1160-4.
    View in: PubMed
    Score: 0.068
  20. Prevalence of type III secretion protein exoenzymes and antimicrobial susceptibility patterns from bloodstream isolates of patients with Pseudomonas aeruginosa bacteremia. J Chemother. 2008 Dec; 20(6):714-20.
    View in: PubMed
    Score: 0.063
  21. Killing activity of rifampin with piperacillin therapy against adherent cells of Pseumodomas aeruginosa. J Chemother. 2008 Oct; 20(5):652-4.
    View in: PubMed
    Score: 0.063
  22. Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea. Ann Pharmacother. 2008 Jun; 42(6):827-35.
    View in: PubMed
    Score: 0.061
  23. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis. 2008 Mar 15; 46(6):862-7.
    View in: PubMed
    Score: 0.060
  24. Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2007 Jul; 58(3):309-14.
    View in: PubMed
    Score: 0.057
  25. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother. 2007 Jan; 51(1):35-9.
    View in: PubMed
    Score: 0.055
  26. Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin Ther. 2006 Aug; 28(8):1208-1216.
    View in: PubMed
    Score: 0.054
  27. A US-based national surveillance study for the susceptibility and epidemiology of Clostridioides difficile isolates with special reference to ridinilazole: 2020-2021. Antimicrob Agents Chemother. 2023 10 18; 67(10):e0034923.
    View in: PubMed
    Score: 0.044
  28. The Integrity of Heme Is Essential for Reproducible Detection of Metronidazole-Resistant Clostridioides difficile by Agar Dilution Susceptibility Tests. J Clin Microbiol. 2021 08 18; 59(9):e0058521.
    View in: PubMed
    Score: 0.038
  29. Cunninghamella bertholletiae infection in a bone marrow transplant patient: amphotericin lung penetration, MIC determinations, and review of the literature. Pharmacotherapy. 2001 Jul; 21(7):855-60.
    View in: PubMed
    Score: 0.038
  30. Cerebrospinal fluid concentrations of quinupristin-dalfopristin in a patient with vancomycin-resistant Enterococcus faecium [correction of faecalis] ventriculitis. Pharmacotherapy. 2001 Jun; 21(6):748-50.
    View in: PubMed
    Score: 0.038
  31. In vitro activity of eravacycline against common ribotypes of Clostridioides difficile. J Antimicrob Chemother. 2020 10 01; 75(10):2879-2884.
    View in: PubMed
    Score: 0.036
  32. In Vitro Activity of Omadacycline, a New Tetracycline Analog, and Comparators against Clostridioides difficile. Antimicrob Agents Chemother. 2020 07 22; 64(8).
    View in: PubMed
    Score: 0.035
  33. Constitutive expression of the cryptic vanGCd operon promotes vancomycin resistance in Clostridioides difficile clinical isolates. J Antimicrob Chemother. 2020 04 01; 75(4):859-867.
    View in: PubMed
    Score: 0.035
  34. Activity of Hospital Disinfectants against Vegetative Cells and Spores of Clostridioides difficile Embedded in Biofilms. Antimicrob Agents Chemother. 2019 12 20; 64(1).
    View in: PubMed
    Score: 0.034
  35. Whole-genome sequencing of Staphylococcus epidermidis bloodstream isolates from a prospective clinical trial reveals that complicated bacteraemia is caused by a limited number of closely related sequence types. Clin Microbiol Infect. 2020 May; 26(5):646.e1-646.e8.
    View in: PubMed
    Score: 0.034
  36. Characterization of Clostridioides difficile ribotypes in domestic dogs in Rio de Janeiro, Brazil. Anaerobe. 2019 Aug; 58:22-29.
    View in: PubMed
    Score: 0.033
  37. Bacteremia in Patients With Liver Cirrhosis: Prevalence and Predictors of Multidrug Resistant Organisms. J Clin Gastroenterol. 2018 08; 52(7):648-654.
    View in: PubMed
    Score: 0.031
  38. In Vitro Evaluation of BacT/Alert FA Blood Culture Bottles and T2Candida Assay for Detection of Candida in the Presence of Antifungals. J Clin Microbiol. 2018 08; 56(8).
    View in: PubMed
    Score: 0.031
  39. Evaluating the Effects of Surotomycin Treatment on Clostridium difficile Toxin A and B Production, Immune Response, and Morphological Changes. Antimicrob Agents Chemother. 2016 06; 60(6):3519-23.
    View in: PubMed
    Score: 0.027
  40. A novel method for imaging the pharmacological effects of antibiotic treatment on Clostridium difficile. Anaerobe. 2016 Aug; 40:10-4.
    View in: PubMed
    Score: 0.026
  41. Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection. J Antimicrob Chemother. 2016 May; 71(5):1245-51.
    View in: PubMed
    Score: 0.026
  42. Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile. Antimicrob Agents Chemother. 2013 Jun; 57(6):2690-3.
    View in: PubMed
    Score: 0.021
  43. Mathematical modeling to characterize the inoculum effect. Antimicrob Agents Chemother. 2010 Nov; 54(11):4739-43.
    View in: PubMed
    Score: 0.018
  44. Changing Clostridium difficile infection testing and treatment trends at a large tertiary care teaching hospital. Pharm World Sci. 2009 Oct; 31(5):565.
    View in: PubMed
    Score: 0.017
  45. Comparative killing rates of gatifloxacin and ciprofloxacin against 14 clinical isolates: impact of bacterial strain and antibiotic concentration. Diagn Microbiol Infect Dis. 2002 Sep; 44(1):59-61.
    View in: PubMed
    Score: 0.010
  46. Bactericidal activity and postantibiotic effect of levofloxacin against anaerobes. Antimicrob Agents Chemother. 1999 Oct; 43(10):2547-9.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.